Los Angeles Capital Management LLC Purchases Shares of 43,422 Replimune Group, Inc. $REPL

Los Angeles Capital Management LLC acquired a new position in shares of Replimune Group, Inc. (NASDAQ:REPL) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 43,422 shares of the company’s stock, valued at approximately $403,000. Los Angeles Capital Management LLC owned 0.06% of Replimune Group at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Deutsche Bank AG grew its holdings in Replimune Group by 0.4% in the first quarter. Deutsche Bank AG now owns 563,701 shares of the company’s stock valued at $5,496,000 after purchasing an additional 2,140 shares during the period. Arizona State Retirement System boosted its holdings in shares of Replimune Group by 19.7% in the 1st quarter. Arizona State Retirement System now owns 15,439 shares of the company’s stock valued at $151,000 after purchasing an additional 2,545 shares during the last quarter. MetLife Investment Management LLC grew its stake in shares of Replimune Group by 7.8% during the 1st quarter. MetLife Investment Management LLC now owns 40,598 shares of the company’s stock valued at $396,000 after buying an additional 2,939 shares during the period. Corebridge Financial Inc. grew its stake in shares of Replimune Group by 11.0% during the 1st quarter. Corebridge Financial Inc. now owns 33,584 shares of the company’s stock valued at $327,000 after buying an additional 3,317 shares during the period. Finally, US Bancorp DE increased its holdings in shares of Replimune Group by 582.6% during the 1st quarter. US Bancorp DE now owns 4,594 shares of the company’s stock worth $45,000 after buying an additional 3,921 shares during the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Price Performance

Shares of NASDAQ REPL opened at $8.99 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.31 and a quick ratio of 6.94. Replimune Group, Inc. has a 1-year low of $2.68 and a 1-year high of $17.00. The company has a market capitalization of $705.18 million, a price-to-earnings ratio of -2.60 and a beta of 0.80. The business has a 50-day moving average of $6.45 and a 200-day moving average of $7.42.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Thursday, November 6th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.03). On average, equities analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on REPL. JPMorgan Chase & Co. upgraded Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 target price on the stock in a report on Monday, October 20th. Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $3.00 to $13.00 in a report on Monday, October 20th. Leerink Partnrs raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Jefferies Financial Group dropped their target price on shares of Replimune Group from $31.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Finally, Piper Sandler upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price target on the stock in a report on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.75.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.